• About Us
    • Contact Us
    • Login
    • ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
About Us Contact Us Login ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
Grand Rounds

More from the PITCHES Trial: Subgroup Analysis of Participants with Intrahepatic Cholestasis of Pregnancy and UDCA Treatment

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • Ursodeoxycholic acid (UDCA), a bile acid, is frequently used to treat intrahepatic cholestasis of pregnancy (ICP), despite limited evidence for its efficacy
  • The PITCHES RCT found no evidence of benefit from UDCA treatment in women with ICP
  • In a secondary analysis of the PITCHES trial, Fleminger et al. (BJOG, 2021) performed a subgroup analysis to determine whether UDCA may benefit particular groups of patients with ICP 

METHODS:

  • Secondary analysis of the PITCHES trial
    • See ‘Related ObG Topics’ below for review of the PITCHES RCT
    • Primary outcome of PITCHES RCT: Composite of perinatal death, preterm delivery and NICU admission
  • Participants
    • Women with ICP
    • Between 20w0d and 40w6d
  • Interventions
    • UDCA
    • Placebo
  • Study design
    • Subgroup definitions
      • Bile acid concentrations: Accepted thresholds related to perinatal risk
      • Itch: Median itch at baseline in the trial participants
  • Primary outcomes
    • Beneficial effect of UDCA on
      • Bile acid concentrations
      • Perceived itching

RESULTS:

  • 527 women
  • Bile acid concentrations decreased in both the UDCA and placebo groups
  • Baseline bile acid concentrations did not impact bile acid response to UDCA treatment
    • In women with baseline bile acid concentrations <40 μmol/l, treatment with UDCA resulted in increased bile acid concentrations but was not statistically significant (P=0.647)
  • In women with a high baseline itch score, there was an improvement in itch response that was not significant (P=0.640)
  • There was a weak relationship between bile acid concentrations and itch severity
  • Results did not change based on whether the analysis was limited to women taking >90% of prescribed medication (self‐report)

CONCLUSION:

  • Subgroup analysis of the PITCHES RCT demonstrated that baseline bile acid concentrations and initial itch scores did not alter response to UDCA in women with ICP
  • Bile acid concentrations did not correlate well with itch
  • The authors conclude

The secondary analysis presented here identified no subgroup of women in whom a reduction in bile acid concentration or itch score in response to treatment with UDCA was found

Routine use of UDCA to reduce bile acid concentrations or itch scores should be reconsidered, and there is no justification for targeting women with high bile acid concentrations or high itch scores at presentation

Learn More – Primary Sources:

Ursodeoxycholic acid in intrahepatic cholestasis of pregnancy: a secondary analysis of the PITCHES trial

Want to stay on top of key guidelines and research papers?

ObGFirst® – Try It Free! »

image_pdfFavoriteLoadingFavorite
< Previous
All Grand Rounds Posts
Next >

Related ObG Topics:

PITCHES RCT: Ursodeoxycholic Acid and Intrahepatic Cholestasis of Pregnancy
Risk of Stillbirth with Intrahepatic Cholestasis of Pregnancy: What do Bile Acid Concentrations Tell Us?
SMFM Recommendations: Intrahepatic Cholestasis of Pregnancy
Is Rifampin an Option for the Treatment of Intrahepatic Cholestasis in Pregnancy?

Sections

  • COVID-19
  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • Now@ObG
  • Media

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Get Guideline Alerts Direct to Your Phone
Try ObGFirst Free!

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site